Skip to Content

A Favorable Safety Profile of IL-23 p19 Inhibitors for Psoriasis

According to dermatologist Andy Blauvelt, the safety of biologics for dermatological diseases such as psoriasis is a significant issue. And he is often asked, ‘’What is the safest one to use?”. New results presented in this MEDtalk indicate a safe and effective profile of IL-23 p19 inhibitors for treating patients with moderate-to-severe plaque psoriasis.

Andy Blauvelt

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top